Today announced that it offers initiated a new Phase III trial made to evaluate the efficacy.

‘We believe pimavanserin has an ideal profile to effectively deal with PDP without impairing electric motor function and, therefore, supplies the potential for an important advance in therapy for sufferers suffering from this large unmet medical need.’.. ACADIA initiates new pimavanserin Phase III trial for Parkinson’s disease psychosis ACADIA Pharmaceuticals Inc. , a biopharmaceutical business utilizing innovative technology to energy drug discovery and clinical development of novel remedies for central nervous program disorders, today announced that it offers initiated a new Phase III trial made to evaluate the efficacy, tolerability and security of pimavanserin as a treatment for patients with Parkinson’s disease psychosis .D., Chief Executive Officer of ACADIA Pharmaceuticals.This article is normally republished with kind permission from our friends at The Kaiser Family members Foundation. You will see the complete Kaiser Daily Health Policy Statement, search the archives, or join email delivery of in-depth coverage of wellness policy developments, debates and discussions. The Kaiser Daily Wellness Policy Report is published for Kaisernetwork.org, a free services of The Henry J. Kaiser Family Foundation.